




Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.4. Antihepatitis medicines > 6.4.4.2. Medicines for hepatitis C > 6.4.4.2.2. Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

ATC codes: J05AP05

Indication	Chronic hepatitis C <span>ICD11 code: 1E91.1</span>
INN	Simeprevir
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 150 mg
EML status history	First added in 2015 (TRS 994) Removed in 2019 (TRS 1021)
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Read more <a href="#">about patents.</a> 
Wikipedia	<a href="#">Simeprevir</a> 
DrugBank	<a href="#">Simeprevir</a> 

### Summary of evidence and Expert Committee recommendations

The Expert Committee considered whether it was appropriate to delete non-pangenotypic treatments for hepatitis C, and recommended the deletion of simeprevir, whose place in therapy was now superseded by the pan-genotypic options. The Committee recommended that other non-pangenotypic treatments could be considered for deletion from the EML in the future.

